Kerry L. Burnstein

Kerry L. Burnstein

Auto-generated profile, based on publicly available information

Kerry L. Burnstein

Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2005 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
KBKerry L. Burnstein
Kerry L. Burnstein

26 December 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RIReema A. Ishteiwy
Reema A. Ishteiwy
TWToby M. Ward
Toby M. Ward
DDDerek M. Dykxhoorn
Derek M. Dykxhoorn
KBKerry L. Burnstein
Kerry L. Burnstein
MicroRNAs (miRs) are small, endogenous, non-coding RNAs that regulate the stability and/or translation of complementary mRNA targets. MiRs have emerged not only as critical modulators of normal physiologic processes, but their deregulation may significantly impact prostate and other cancers. The expression of miR-23b and miR-27b, which are encoded by the same miR cluster (miR-23b/-27b), are downregulated in metastatic, castration-resistant tumors compared to primary prostate cancer and benign tissue; however, their possible role in prostate cancer progression is unknown. We found that ectopic expression of miR-23b/-27b in two independent castration-resistant prostate cancer cell lines resulted in suppression of invasion and migration, as well as reduced survival in soft agar (a measure of anoikis). However, there was no effect of miR-23b/-27b on cell proliferation suggesting that these miRs function as metastasis (but not growth) suppressors in prostate cancer. Conversely, inhibition of miR-23b/-27b in the less aggressive androgen-dependent LNCaP prostate cancer cell line resulted in enhanced invasion and migration also without affecting proliferation. Mechanistically, we found that introduction of miR-23b/-27b in metastatic, castration-resistant prostate cancer cell lines resulted in a significant attenuation of Rac1 activity without affecting total Rac1 levels and caused increased levels of the tumor suppressor E-cadherin. Inhibition of these miRs had the opposite effect in androgen-dependent LNCaP cells. These results suggest that miR-23b/-27b are metastasis suppressors that might serve as novel biomarkers and therapeutic agents for castration-resistant disease.

1 March 2009 in Molecular Endocrinology
Verified
Journal Article
Open access
PDF file
ARAdena E. Rosenblatt
Adena E. Rosenblatt
KBKerry L. Burnstein
Kerry L. Burnstein
Environmental sodium arsenite is a toxin that is associated with male infertility due to decreased and abnormal sperm production. Arsenic trioxide (ATO), another inorganic trivalent semimetal, is an effective therapy for acute promyelocytic leukemia, and there is investigation of its possible efficacy in prostate cancer. However, the mechanism of arsenic action in male urogenital tract tissues is not clear. Because the androgen receptor (AR) plays an important role in spermatogenesis and prostate cancer, we explored the possibility that trivalent arsenic regulates AR function. We found that arsenic inhibited AR transcriptional activity in prostate cancer and Sertoli cells using reporter gene assays testing several androgen response element-containing regions and by assessing native target gene expression. Arsenic inhibition of AR activity was not due to down-regulation of AR protein levels, decreased hormone binding to AR, disruption of AR nuclear translocation, or interference with AR-DNA binding in vitro. However, chromatin immunoprecipitation studies revealed that arsenic inhibited AR recruitment to an AR target gene enhancer in vivo. Consistent with a deficiency in AR-chromatin binding, arsenic disrupted AR amino and carboxyl termini interaction. Furthermore, ATO caused a significant decrease in prostate cancer cell proliferation that was more pronounced in cells expressing AR compared with cells depleted of AR. In addition, inhibition of AR activity by ATO and by the AR antagonist, bicalutamide, was additive. Thus, arsenic-induced male infertility may be due to inhibition of AR activity. Further, because AR is an important target in prostate cancer therapy, arsenic may serve as an effective therapeutic option.

10 February 2010 in Endocrinology
Verified
Journal Article
Open access
PDF file
OFOmar Flores
Omar Flores
ZWZhengying Wang
Zhengying Wang
KKKaren E. Knudsen
Karen E. Knudsen
KBKerry L. Burnstein
Kerry L. Burnstein
1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3), inhibits proliferation of a variety of cell types including adenocarcinoma of the prostate. We have previously shown that 1,25-(OH)2D3 increases the stability of the cyclin-dependent kinase inhibitor p27KIP1, decreases cyclin-dependent kinase 2 (CDK2) activity, and promotes G1 phase accumulation in human prostate cancer cells. These effects correlate with cytoplasmic relocalization of CDK2. In this study, we investigated the role of CDK2 cytoplasmic relocalization in the antiproliferative effects of 1,25-(OH)2D3. CDK2 was found to be necessary for prostate cancer cell proliferation. Although induced by 1,25-(OH)2D3, the cyclin-dependent kinase inhibitor p27KIP1 was dispensable for 1,25-(OH)2D3-mediated growth inhibition. Reduction in CDK2 activity by 1,25-(OH)2D3 was associated with decreased T160 phosphorylation, a residue whose phosphorylation in the nucleus is essential for CDK2 activity. Ectopic expression of cyclin E was sufficient to overcome 1,25-(OH)2D3-mediated cytoplasmic mislocalization of CDK2 and all antiproliferative effects of 1,25-(OH)2D3, yet endogenous levels of cyclin E or binding to CDK2 were not affected by 1,25-(OH)2D3. Similarly, knockdown of the CDK2 substrate retinoblastoma, which causes cyclin E up-regulation, resulted in resistance to 1,25-(OH)2D3-mediated growth inhibition. Human prostate cancer cells resistant to growth inhibition by 1,25-(OH)2D3 but retaining fully functional vitamin D receptors were developed. These cells did not exhibit 1,25-(OH)2D3-mediated cytoplasmic relocalization of CDK2. Targeting CDK2 to the nucleus of 1,25-(OH)2D3-sensitive cancer cells blocked G1 accumulation and growth inhibition by 1,25-(OH)2D3. These data establish central roles for CDK2 nuclear-cytoplasmic trafficking and cyclin E in the mechanism of 1,25-(OH)2D3-mediated growth inhibition in prostate cancer cells.

6 January 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
CFCale D. Fahrenholtz
Cale D. Fahrenholtz
FRFerenc G. Rick
Ferenc G. Rick
MGMaria I. Garcia
Maria I. Garcia
MZMarta Zarandi
Marta Zarandi
RCRen-Zhi Cai
Ren-Zhi Cai
KBKerry L. Burnstein
Kerry L. Burnstein
Significance: Therapeutic options for recurrent castration-resistant prostate cancer (CRPC) are limited and more effective treatment regimens are needed. Antagonists of growth hormone-releasing hormone (GHRH) inhibit growth of experimental models of human cancer cells, including prostate cancer, by suppressing the actions of tumoral growth factors, particularly GHRH itself, which is an autocrine/paracrine growth factor in many tumors. Here we investigated the antitumor effects of the latest series of highly potent GHRH antagonists—MIA-602, MIA-606, and MIA-690—on androgen-dependent as well as CRPC lines expressing receptors for GHRH. MIA-602 inhibited in vivo growth of both androgen-dependent and CRPCs and decreased cell proliferation in vitro. This study provides evidence of the preclinical efficacy of GHRH antagonist MIA-602 in the treatment of human prostate cancer.

26 June 2019 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
NZNing Zhao
Ning Zhao
SPStephanie O. Peacock
Stephanie O. Peacock
CLChen Hao Lo
Chen Hao Lo
LHLaine M. Heidman
Laine M. Heidman
MRMeghan A. Rice
Meghan A. Rice
KBKerry L. Burnstein
Kerry L. Burnstein
Castration-resistant prostate cancer (CRPC) recurs after androgen deprivation therapy (ADT) and is incurable. Reactivation of androgen receptor (AR) signaling in the low androgen environment of ADT drives CRPC. This AR activity occurs through a variety of mechanisms, including up-regulation of AR coactivators such as VAV3 and expression of constitutively active AR variants such as the clinically relevant AR-V7. AR-V7 lacks a ligand-binding domain and is linked to poor prognosis. We previously showed that VAV3 enhances AR-V7 activity to drive CRPC progression. Gene expression profiling after depletion of either VAV3 or AR-V7 in CRPC cells revealed arginine vasopressin receptor 1a (AVPR1A) as the most commonly down-regulated gene, indicating that this G protein–coupled receptor may be critical for CRPC. Analysis of publicly available human PC datasets showed that AVPR1A has a higher copy number and increased amounts of mRNA in advanced PC. Depletion of AVPR1A in CRPC cells resulted in decreased cell proliferation and reduced cyclin A. In contrast, androgen-dependent PC, AR-negative PC, or nontumorigenic prostate epithelial cells, which have undetectable AVPR1A mRNA, were minimally affected by AVPR1A depletion. Ectopic expression of AVPR1A in androgen-dependent PC cells conferred castration resistance in vitro and in vivo. Furthermore, treatment of CRPC cells with the AVPR1A ligand, arginine vasopressin (AVP), activated ERK and CREB, known promoters of PC progression. A clinically safe and selective AVPR1A antagonist, relcovaptan, prevented CRPC emergence and decreased CRPC orthotopic and bone metastatic growth in mouse models. Based on these preclinical findings, repurposing AVPR1A antagonists is a promising therapeutic approach for CRPC.